scholarly journals Oocyte cryopreservation: a feasible fertility preservation option for reproductive age cancer survivors

2010 ◽  
Vol 27 (8) ◽  
pp. 495-499 ◽  
Author(s):  
Nicole Noyes ◽  
Patty Ann Labella ◽  
James Grifo ◽  
Jaime M. Knopman
Keyword(s):  
Cancer Survivors ◽  
Fertility Preservation ◽  
Reproductive Age ◽  
Oocyte Cryopreservation

Referral trends for reproductive-age patients with breast cancer to a reproductive endocrinology clinic for fertility preservation counseling between 2004 and 2012.

2013 ◽  
Vol 31 (26_suppl) ◽  
pp. 129-129
Author(s):  
Jonathan David Kort ◽  
Kira Seiger ◽  
Solomon Henry ◽  
Lynn Westphal
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Fertility Preservation ◽  
Reproductive Age ◽  
Oocyte Cryopreservation ◽  
Cancer Center ◽  
Research Database ◽  
Breast Cancer Patients ◽  
Reproductive Endocrinology ◽  
Patients Âgés

129 Background: As of October 2012, both embryo and oocyte cryopreservation are considered non-experimental fertility preservation (FP) options for cancer patients facing potentially gonadotoxic therapy. This study aims to assess the historical referral frequency of reproductive aged breast cancer patients from a major cancer center to an associated reproductive endocrinology and infertility (REI) clinic for counseling regarding FP and also assess how frequently these patients underwent FP after referral. Methods: Using the Stanford Cancer Center Research Database in conjunction with our EMR, a query was made for patients of reproductive age (13-45) who were seen at the Stanford Cancer Center for a new breast cancer diagnosis between 2004 and 2012. These patients’ records were then searched for referral encounters in the REI department. Those who were seen by REI were assessed for having undergone FP via embryo or oocyte cryopreservation prior to starting chemotherapy. Results: 420 women, ages 20 to 45, were seen at our cancer center for a new diagnosis of breast cancer between 2004 and 2012. Sixty (14.3%) of these patients, ages 20 to 42 at diagnosis, were referred to the REI department for FP counseling. Patients who were referred for FP counseling were 5.1 years younger at diagnosis than those who were not (p<.005). Of those referred, 33.3% underwent FP with embryo (77%) or oocyte cryopreservation (23%) under an experimental protocol. Among breast cancer patients ≤35 years old, 35% were referred to our REI department for FP counseling and 53.5% of those referred underwent FP. Conclusions: Despite advances in FP technology, the majority of reproductive aged breast cancer patients are still not referred for FP counseling by a reproductive endocrinologist. This trend was also seen among patients younger than 35—a subgroup who is more likely to undergo and benefit most from FP. This study does not reflect patients who decline this opportunity or seek FP elsewhere, however additional study and outreach is needed to improve referral rates, which are now a measure of the Quality Oncology Practice Initiative (QOPI).

scholarly journals Established and Future Promising Fertility Preservation Options in Adolescence and Adults

2017 ◽  
Vol 3 (1) ◽  
pp. 1
Author(s):  
Hossein Yazdekhasti ◽  
Zahra Rajabi
Keyword(s):  
Cancer Survivors ◽  
Fertility Preservation ◽  
Recent Progress ◽  
Cancer Prognosis ◽  
Oocyte Cryopreservation ◽  
Embryo Cryopreservation ◽  
Advantages And Disadvantages ◽  
The Past ◽  
Tissue Cryopreservation ◽  
Cancer Diseases

Over the past decades, due to a high number of cancer survivors, the demands for fertility preservation have been raised dramatically, and this might come from recent progress in the cancer prognosis and diagnosis procedures. For those who are involved in cancer diseases, there are multiple options regarding their fertility preservation which can be selected based on patient’s age, the risk of gonadal involvement, the time available and the type of cancer with different advantages and disadvantages. Among all possible options, embryo cryopreservation for females and semen freezing for males are the most applicable method, however other options such as gonadal tissue cryopreservation, and oocyte cryopreservation are other promising options which would be considered if the partner was not available. As conclusion, this is noteworthy that women with cancer must benefit from adequate consultations regarding their possible fertility preservation options and immediate correct consultations definitely can help families to make their mind to choose best available options.

Ethical Quandaries in Gamete-Embryo Cryopreservation Related to Oncofertility

2013 ◽  
Vol 41 (3) ◽  
pp. 711-719 ◽  
Author(s):  
Leslie Ayensu-Coker ◽  
Ellen Essig ◽  
Lesley L. Breech ◽  
Steven Lindheim
Keyword(s):  
Cancer Survivors ◽  
Fertility Preservation ◽  
Reproductive Potential ◽  
Reproductive Age ◽  
Embryo Cryopreservation ◽  
Fertility Awareness ◽  
Men And Women ◽  
Current Therapies ◽  
American Society ◽  
Prevalence Of Cancer

Cancer rates in men and women of reproductive age have continued to increase in recent years; however, therapy has dramatically decreased the mortality rates. Since 1990, the prevalence of cancer survivors in young adults increased from 1 in 1,000 to 1 in 250 patients due to more aggressive therapies. Current therapies may have profound toxic effects on gamete function with infertility as an expected consequence of cancer therapy. Depending on the site and stage of cancer, age of the patient, and the type of treatment, approximately 90% of men and women diagnosed with cancer may be at risk of permanent infertility.Fertility preservation has emerged as a discipline dedicated to improving the future reproductive potential of cancer survivors. Significant progress in the advancement of fertility preservation therapies and a heightened awareness of the availability of therapies has occurred in the past 10 years. The American Society of Clinical Oncology (ASCO) and the American Society of Reproductive Medicine (ASRM) have advanced these efforts by formally recognizing the importance of fertility awareness.

scholarly journals Young adult female cancer survivors' unmet information needs and reproductive concerns contribute to decisional conflict regarding posttreatment fertility preservation

Cancer ◽  
2016 ◽  
Vol 122 (13) ◽  
pp. 2101-2109 ◽  
Author(s):  
Catherine Benedict ◽  
Bridgette Thom ◽  
Danielle N. Friedman ◽  
Debbie Diotallevi ◽  
Elaine M. Pottenger ◽  
...  
Keyword(s):  
Young Adult ◽  
Cancer Survivors ◽  
Fertility Preservation ◽  
Adult Female ◽  
Information Needs ◽  
Decisional Conflict ◽  
Reproductive Concerns ◽  
Female Cancer Survivors

Sex Differences in Fertility-Related Information Received by Young Adult Cancer Survivors

2012 ◽  
Vol 30 (17) ◽  
pp. 2147-2153 ◽  
Author(s):  
Gabriela M. Armuand ◽  
Kenny A. Rodriguez-Wallberg ◽  
Lena Wettergren ◽  
Johan Ahlgren ◽  
Gunilla Enblad ◽  
...  
Keyword(s):  
Sex Differences ◽  
Cancer Survivors ◽  
Population Based ◽  
Postal Questionnaire ◽  
Reproductive Age ◽  
Young Adult Cancer Survivors ◽  
Related Information ◽  
Desire To Have Children ◽  
Adult Cancer Survivors ◽  
Male Sex

Purpose The aim was to investigate male and female cancer survivors' perception of fertility-related information and use of fertility preservation (FP) in connection with cancer treatment during reproductive age. Methods The study sample consisted of cancer survivors diagnosed from 2003 to 2007 identified in population-based registers in Sweden. Inclusion criteria included survivors who were age 18 to 45 years at diagnosis and had lymphoma, acute leukemia, testicular cancer, ovarian cancer, or female breast cancer treated with chemotherapy. Of 810 eligible participants, 484 survivors (60% response rate) completed a postal questionnaire. Results The majority of male participants reported having received information about treatment impact on fertility (80%) and FP (68%), and more than half of the men banked frozen sperm (54%). Among women, less than half (48%) reported that they received information about treatment impact on fertility, and 14% reported that they received information about FP. Only seven women (2%) underwent FP. Predictors for receiving information about treatment impact on fertility were a pretreatment desire to have children (odds ratio [OR], 3.5), male sex (OR, 3.2), and being ≤ 35 years of age at diagnosis (OR, 2.0). Predictors for receiving information about FP included male sex (OR, 14.4), age ≤ 35 at diagnosis (OR, 5.1), and having no children at diagnosis (OR, 2.5). Conclusion Our results show marked sex differences regarding the receipt of fertility-related information and use of FP. There is an urgent need to develop fertility-related information adapted to female patients with cancer to improve their opportunities to participate in informed decisions regarding their treatment and future reproductive ability.

Fertility Preservation

2018 ◽  
Author(s):  
Chantae S Sullivan-Pyke ◽  
Clarisa Gracia
Keyword(s):  
Fertility Preservation ◽  
Ovarian Tissue ◽  
Testicular Tissue ◽  
Mature Oocyte ◽  
Gonadotropin Releasing Hormone ◽  
Oocyte Cryopreservation ◽  
Ovarian Tissue Cryopreservation ◽  
Embryo Cryopreservation ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Tissue Cryopreservation

Fertility preservation has becoming increasingly important for patients at risk for gonadal failure, including those needing treatment for cancer or autoimmune conditions, genetic conditions that predispose to gonadal insufficiency, and age-related fertility decline. Embryo cryopreservation and mature oocyte cryopreservation are the standards for fertility preservation in postpubertal women. Ovarian tissue cryopreservation and gonadotropin-releasing hormone agonist use for ovarian suppression are experimental methods that may be offered to patients for whom embryo and/or mature oocyte cryopreservation are not applicable. The cryopreservation of spermatozoa is the standard for fertility preservation in postpubertal males, but testicular tissue cryopreservation may be offered to prepubertal males.   This review contains 10 figures, 6 tables and 53 references Key words: controlled ovarian stimulation, embryo cryopreservation, gonadotropin-releasing hormone agonist, in vitro maturation, oocyte cryopreservation, ovarian tissue cryopreservation, sperm extraction, testicular tissue cryopreservation  

Fertility preservation medicine: A new field in the care of young cancer survivors-response

2009 ◽  
Vol 53 (6) ◽  
pp. 1160-1160
Author(s):  
Kutluk Oktay ◽  
Murat Sonmezer ◽  
Ozgur Oktem
Keyword(s):  
Cancer Survivors ◽  
Fertility Preservation

scholarly journals Fertility preservation and decisional regret in young breast cancer survivors: A longitudinal analysis.

2017 ◽  
Vol 35 (5_suppl) ◽  
pp. 106-106
Author(s):  
Samantha Rose Dewald ◽  
Loki Natarajan ◽  
Irene Su
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Fertility Preservation ◽  
Repeated Measures ◽  
Breast Cancer Survivors ◽  
Ovarian Function ◽  
Future Fertility ◽  
Young Breast Cancer ◽  
Decisional Regret ◽  
Over Time

106 Background: Fertility is important to many young breast cancer survivors (YBCS), who face difficult decisions on whether to undergo fertility preservation prior to treatment. Because few longitudinal data assessing decisional regret are available, the objectives of this study were to assess longitudinal changes in decisional regret on fertility preservation following breast cancer diagnosis; determine if fertility preservation treatment decisions are related to decreased decisional regret. Methods: From 3 academic breast cancer programs, 169 YBCS younger than age 45 were recruited at diagnosis between 2009 and 2012 and followed prospectively for ovarian function. Participants completed questionnaires on fertility preservation choices and the Decisional Regret Scale (DRS) during study visits every 6 months for up to 5 years. DRS is scored 0 (no regret) to 100 (highest regret). DRS was dichotomized as none versus any decisional regret. Generalized linear models estimated the change in DRS over time and the association between patient characteristics and DRS. Results: Mean age at diagnosis was 38.7 (SD 4.8). Median total follow-up was 176 days (IQR 84 to 1415 days). Enrollment DRS was available for 89 women; 48% reported decisional regret about fertility preservation (median DRS=20). Participants worried about future fertility were more likely to report decisional regret (p=0.009). 31% underwent fertility preservation, but this was not associated with decisional regret (p=0.65). In repeated measures analysis for the entire cohort, no significant change in DRS occurred over this time period (OR 0.8, 95% CI 0.4-1.7). Worry about future fertility remained significantly associated with DRS over time (OR 55.1, 95% CI 7.7-395.1). Conclusions: In a cohort of YBCS, experiencing decisional regret about fertility preservation persists for years after diagnosis. Those worried about future fertility are more likely to experience decisional regret regarding fertility preservation.

scholarly journals Addressing decisional conflict about fertility preservation: helping young female cancer survivors’ family planning decisions

2017 ◽  
Vol 44 (3) ◽  
pp. 175-180 ◽  
Author(s):  
Madleina Müller ◽  
Corinne Urech ◽  
Jacky Boivin ◽  
Verena Ehrbar ◽  
Rebecca Moffat ◽  
...  
Keyword(s):  
Family Planning ◽  
Cancer Survivors ◽  
Cancer Patients ◽  
Fertility Preservation ◽  
Decisional Conflict ◽  
Young Female ◽  
University Education ◽  
Time Interval ◽  
Related Factors ◽  
Female Cancer Patients

BackgroundHealth professionals are challenged by a growing number of young long-term cancer survivors with their specific needs with regard to family planning. This study aimed at assessing decisional conflict (DC) in young female cancer patients regarding fertility preservation, identifying demographic, fertility and fertility preservation related factors, which may affect DC, and assessing the helpfulness of various decision-supports.MethodsA retrospective, cross-sectional, web-based survey via an online questionnaire available in three languages with specific items concerning cancer, fertility, fertility preservation and the validated Decisional Conflict Scale targeted at current or former female cancer patients aged 18–45 years, with cancer types or treatment potentially affecting reproductive function.ResultsThe 155 participating women showed considerable DC, especially with regard to missing information and support. DC was significantly lower in patients when the risk of infertility was discussed with a health professional, when they had undergone any procedure to preserve fertility, and when they had a university education. A longer time interval since cancer diagnosis was associated with higher DC. The most helpful decision-support tools were specialised websites and leaflets.ConclusionsYoung female cancer patients’ DC with regard to fertility preservation is very high. Information and support seem to be deficient. More information through standardised information tools might be an effective strategy to lower their DC at the time when treatment decisions need to be taken, and to improve their reproductive health after they have overcome cancer in the future.

Sign in / Sign up

Export Citation Format

Share Document